Related Experiment Video
Updated: Feb 6, 2026

Acute Myocardial Infarction in Rats
Published on: February 16, 2011
Conventional Dendritic Cells Impair Recovery after Myocardial Infarction
Jun Seong Lee1,2,3, Se-Jin Jeong4, Sinai Kim4
1Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec H3T 1J4, Canada.
Insights
Conventional dendritic cells (cDCs) worsen heart damage after myocardial infarction (MI). Depleting cDCs improves cardiac function and reduces inflammation, revealing their pathological role in heart repair.
Area of Science:
- Immunology
- Cardiology
- Pathology
Background:
- Myocardial infarction (MI) triggers sterile cardiac inflammation and tissue repair, processes regulated by mononuclear phagocytes.
- The specific roles of cardiac mononuclear phagocyte subsets, particularly dendritic cells, in cardiovascular disease pathogenesis remain unclear.
Purpose of the Study:
- To investigate the functional contribution of specific cardiac dendritic cell (DC) subsets to cardiac injury and repair following myocardial infarction.
- To identify and characterize murine and human DC populations within the heart.
Main Methods:
- Utilized lineage tracing and genetic studies to identify CD103+ conventional DC1s (cDC1s), CD11b+ conventional DC2s (cDC2s), and plasmacytoid DCs (pDCs) in murine and humanized mouse hearts.
- Assessed cardiac function, remodeling, fibrosis, and inflammatory cell infiltration after MI in DC-depleted models.
Main Results:
- Specific depletion of cDCs, but not pDCs, significantly improved cardiac function and prevented adverse cardiac remodeling post-MI.
- Reduced infarct zone fibrosis, cell area, and inflammatory cell infiltration (macrophages, neutrophils, T cells) were observed in cDC-depleted hearts.
- Depletion of cDCs led to decreased expression of pro-inflammatory cytokines IL-1β and IFN-γ.
Conclusions:
- Conventional dendritic cells play a critical pathological role in the response to myocardial infarction.
- Targeting cDCs may represent a therapeutic strategy to mitigate cardiac damage and improve outcomes after MI.
Abstract:
Ischemic myocardial injury results in sterile cardiac inflammation that leads to tissue repair, two processes controlled by mononuclear phagocytes. Despite global burden of cardiovascular diseases, we do not understand the functional contribution to pathogenesis of specific cardiac mononuclear phagocyte lineages, in particular dendritic cells. To address this limitation, we used detailed lineage tracing and genetic studies to identify bona fide murine and human CD103+ conventional dendritic cell (cDC)1s, CD11b+ cDC2s, and plasmacytoid DCs (pDCs) in the heart of normal mice and immunocompromised NSG mice reconstituted with human CD34+ cells, respectively. After myocardial infarction (MI), the specific depletion of cDCs, but not pDCs, improved cardiac function and prevented adverse cardiac remodeling. Our results showed that fractional shortening measured after MI was not influenced by the absence of pDCs. Interestingly, however, depletion of cDCs significantly improved reduction in fractional shortening. Moreover, fibrosis and cell areas were reduced in infarcted zones. This correlated with reduced numbers of cardiac macrophages, neutrophils, and T cells, indicating a blunted inflammatory response. Accordingly, mRNA levels of proinflammatory cytokines IL-1β and IFN-γ were reduced. Collectively, our results demonstrate the unequivocal pathological role of cDCs following MI.
Related Concept Videos
Sign Convention
The normal force acts perpendicular to the beam's cross-section and can...
Neurons: The Cell Body and the Dendrites
Enolate Mechanism Conventions
Muscle Recovery and Fatigue
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

